| Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma |
NCT03364985: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers |
|
|
| Completed | 1 | 123 | RoW | DWP16001, Placebo, Dapagliflozin | Daewoong Pharmaceutical Co. LTD. | Healthy | 05/19 | 07/19 | | |
NCT04064073: Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study) |
|
|
| Completed | 1 | 34 | RoW | DWP16001, Metformin IR, DWP16001+Metformin IR | Daewoong Pharmaceutical Co. LTD. | Healthy | 11/19 | 11/19 | | |
NCT04343547: Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults |
|
|
| Unknown status | 1 | 34 | RoW | DWP16001, DWC202001+DWC202002, DWP16001+DWC202001+DWC202002 | Daewoong Pharmaceutical Co. LTD. | Healthy | 07/20 | 07/20 | | |
| Unknown status | 1 | 35 | NA | DWP16001 | Daewoong Pharmaceutical Co. LTD. | Type2 Diabetes | 08/20 | 10/20 | | |
NCT05414591: Pharmacokinetics and Safety Following Administration of DWP16001 |
|
|
| Completed | 1 | 38 | RoW | DWP16001 drug A, DWP16001 drug B | Daewoong Pharmaceutical Co. LTD. | Healthy | 08/21 | 08/21 | | |
NCT05207176: Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities |
|
|
| Not yet recruiting | 1 | 24 | NA | DWP16001 | Daewoong Pharmaceutical Co. LTD. | Healthy | 04/22 | 08/22 | | |
NCT05192395: A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers |
|
|
| Completed | 1 | 37 | RoW | DWJ1525, DWP16001, DWC202101 | Daewoong Pharmaceutical Co. LTD. | Healthy | 05/22 | 05/22 | | |
NCT05321732: The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults |
|
|
| Enrolling by invitation | 1 | 24 | RoW | DWP16001, DWP202010 | Daewoong Pharmaceutical Co. LTD. | Healthy Volunteers | 08/22 | 08/22 | | |
NCT05465668: Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and C |
|
|
| Completed | 1 | 43 | RoW | DWP16001 Drug A, DWP16001 Drug C | Daewoong Pharmaceutical Co. LTD. | Healthy Volunteers | 08/22 | 11/22 | | |
NCT05500898: Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults |
|
|
| Not yet recruiting | 1 | 53 | NA | DWP16001, DWC202204+DWC202205, DWP16001+DWC202204+DWC202205 | Daewoong Pharmaceutical Co. LTD. | Healthy | 10/22 | 02/23 | | |
NCT05737771: To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination |
|
|
| Recruiting | 1 | 40 | RoW | DWC202213, DWJ1563, DWP16001 | Daewoong Pharmaceutical Co. LTD. | FDC, Diabetes Mellitus, Type 2 | 03/23 | 06/23 | | |
NCT05797922: To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers |
|
|
| Recruiting | 1 | 32 | RoW | DWP16001, DWP16001 0.3mg | Daewoong Pharmaceutical Co. LTD. | Healthy | 05/23 | 11/23 | | |
NCT05747664: To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function |
|
|
| Recruiting | 1 | 24 | RoW | DWP16001, DWP16001 0.3mg | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Type 2 | 04/24 | 04/24 | | |
